Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.

Social determinants of health (SDOH) are considered the root cause of health inequities, driving as much as 60-80% of health outcomes. These are the conditions in which people are born, grow, live, work, and age. Interest in SDOH data is increasing for several reasons, including calls for representativeness in clinical studies, documentation of patients’ needs, and identification of social programs to help alleviate these needs.

The COVID pandemic’s disparate impacts on different populations has highlighted these issues and the urgency in addressing them. Increasingly recognized is that such data are needed to ensure comparative effectiveness research (CER) and health technology assessments (HTA) do not ignore health care interventions potential impacts on health disparities. Without this attention, we cannot assess whether implementation of new interventions is likely to reduce disparities or perhaps even exacerbate them.

Examples of these use cases are shared, highlighting at least one of the following conditions: diabetes, prostate cancer, Chronic Kidney Disease (CKD), human immunodeficiency virus (HIV), and heart failure.

Key Topics Include:

  • Define SDOH and its influence on health outcomes
  • Understand why SDOH is important to regulators, payers, and other stakeholders
  • Describe the benefits of linking SDOH data with other real-world data when conducting health economics and outcomes research (HEOR)
  • Identify SDOH that may influence the outcomes of select conditions



Senior Vice President
Real-World Evidence and HEOR Strategy
Magnolia Market Access

Pamela Landsman-Blumberg is an industry recognized subject matter expert in real world data (RWD) evaluation and real world evidence (RWE) generation. Her work product has improved the evidence- and value-based decision making of payers, providers, and policymakers. Pam currently advises industry and trade associations on all aspects of fit-for-purpose RWD, RWE, and HEOR strategy.

Chief Science Officer
Innovation and Value Initiative

Dr. Rick Chapman is Chief Science Officer for the Innovation and Value Initiative (IVI), a nonprofit advancing the science, practice, and use of value assessment. Dr. Chapman was Director of Health Economics at the Institute for Clinical and Economic Review (ICER) prior to IVI. Before ICER, Dr. Chapman conducted health economics and outcomes research as a consultant.

Production Partner

Magnolia Market Access

Magnolia Market Access provides tailored strategies and insights to pharmaceutical companies, device manufacturers, and trade associations meeting their market access, HEOR, and healthcare policy needs. Our experts provide 360-degree perspectives and spotlight data to shape policy, communicate value, secure reimbursement, and drive patient access.

Additional Content From Magnolia Market Access

Related Content

The role of patient-centric technologies & tokenization in RWE studies

The role of patient-centric technologies & tokenization in RWE studies

Join the Castor team on the 3rd May 2023 with Aaron Berger from UBC & Ryan Moog from Datavant where we will dive deep into all things RWE, patient-centric technologies and the role of tokenization in clinical trials. You will hear about RWE case studies from the experts, learn new trends in the adoption of DCTs and how the role of patient-centric technologies & tokenization can contribute to successful RWE studies.